BMS launches selective cardiac myosin inhibitor drug in India
Bristol Myers Squibb (BMS) has expanded its therapeutic offerings in India into cardiology with the launch of selective cardiac myosin inhibitor Kopozgo (Mavacamten). The development builds on the company’s strong presence in oncology and haematology, BMS said in a release on launch of the drug for treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). […]
Continue Reading
